Gilead Sciences (GILD) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 6, 2024, might help the stock move higher if these key numbers are better ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manufactu ...

Gilead Sciences (GILD) closed at $79.07 in the latest trading session, marking a -0.57% move from the prior day. This change lagged the S&P 500's daily gain of 0.76%. Meanwhile, the Dow gained 0.59%, and the Nasdaq, a tech-heavy index, added 1.12%.The HIV and hepatitis C drugmaker's shares have seen a decrease of 1.84% over the last month, not keeping up with the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.Analysts and investors alike will be keeping a close eye on the performance of Gilea ...

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gi ...

The latest trading session saw Gilead Sciences (GILD) ending at $79.48, denoting a +1.34% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.29%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq gained 0.43%.The HIV and hepatitis C drugmaker's shares have seen a decrease of 1.54% over the last month, not keeping up with the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.The investment community will be paying close attentio ...

Shares of Gilead Sciences, Inc. (GILD) were down 10.15% after it announced that the late-stage study evaluating oncology drug Trodelvy (sacituzumab govitecan) in previously treated metastatic non-small cell lung cancer (“NSCLC”) failed.The phase III study, EVOKE-01, evaluated Trodelvy vis-à-vis docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. The study enrolled 603 participants who were randomized equally in ...

Pharmaceutical sector mainstay Gilead Sciences (GILD -10.15%) has had many good days on the stock exchange, but Monday wasn't one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company's share price down by more than 10%. And that was on a day when the bellwether S&P 500 index ended in positive territory, rising almost 0.3%.Trodelvy didn't meet its latest primary endpointThat trial was a late-stage one for Trodelvy, an approved cance ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial.The results are a blow to Gilead, which is working to become a power player in the cancer space. The treatment, Trodelvy, is one of Gilead's best-selling cancer drugs, contributing roughly a third of its $769 million in oncology sales during the third quarter.The phase-three study is part of an effort to expand the use of Trodelvy, ...